Yayınlar & Eserler

Yayın Ağı
Makaleler 6
Tümü (6)
SCI-E, SSCI, AHCI (6)
SCI-E, SSCI, AHCI, ESCI (6)
Scopus (4)

1. Effect of CD34⁺ Total/Myeloid CD34⁺ Cell Progenitors and B-Lymphoid Progenitors Within the Bone Marrow Grafts on the Hematopoietic Recovery After Hematopoietic Stem Cell Transplantation.

DALVA K., Haskologlu S., DALVA AYDEMİR S., ÖZ M. D., ÖZTÜRK BİRGE A., Ipek S., et al.
Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation , cilt.20, sa.10, ss.937-944, 2022 (SCI-Expanded, Scopus) identifier identifier identifier

2. Significance of inhibitory maternal killer-cell immunoglobulin-like receptor (KIR) and fetal KIR ligand genotype combinations in placenta related obstetric complications

Orgul G., DALVA K., DALVA AYDEMİR S., Alniacik R. G., DÖNMEZ H. G., Cakar A. N., et al.
JOURNAL OF REPRODUCTIVE IMMUNOLOGY , cilt.148, 2021 (SCI-Expanded, Scopus) identifier identifier identifier

3. Toward In Vitro Epigenetic Drug Design for Thyroid Cancer: The Promise of PF-03814735, an Aurora Kinase Inhibitor

Dalva-Aydemir S., AKYERLİ BOYLU C., Yuksel S. K., Keskin H., Yakicier M. C.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY , cilt.23, sa.10, ss.486-495, 2019 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma identifier identifier identifier

4. Targeting the Metabolic Plasticity of Multiple Myeloma with FDA-Approved Ritonavir and Metformin

Dalva-Aydemir S., Bajpai R., Martinez M., Adekola K. U. A., Kandela I., Wei C., et al.
CLINICAL CANCER RESEARCH , cilt.21, sa.5, ss.1161-1171, 2015 (SCI-Expanded, Scopus) Creative Commons License identifier

5. Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin

Adekola K. U. A., DALVA AYDEMİR S., Ma S., Zhou Z., Rosen S. T., Shanmugam M.
LEUKEMIA & LYMPHOMA , cilt.56, sa.2, ss.450-459, 2015 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier

6. Expression and phosphorylation of the AS160_v2 splice variant supports GLUT4 activation and the Warburg effect in multiple myeloma.

Cheng J. C., McBrayer S. K., Coarfa C., Dalva-Aydemir S., Gunaratne P. H., Carpten J. D., et al.
Cancer & metabolism , cilt.1, sa.1, ss.14, 2013 (SCI-Expanded) Creative Commons License identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. Targeting Glycolysis and Compensatory Mitochondrial Metabolism In An In Vivo Xenograft Model Of Multiple Myeloma With FDA Approved Ritonavir and Metformin

Dalva-Aydemir S., Adekola K. U. A., Koblinski J., Raje N., Rosen S. T., Shanmugam M.
55th Annual Meeting of the American-Society-of-Hematology, Louisiana, Amerika Birleşik Devletleri, 7 - 10 Aralık 2013, cilt.122, (Özet Bildiri) identifier
Kitaplar 2

1. Kanser Tedavisinde Monokonal Antikorların Yeri

Dalva K., Dalva Aydemir S.
Kanser İmmunoterapisinde Güncel Gelişmeler, Prof. Dr. Asuman SUNGUROĞLU, Editör, Turkiye Klinikleri, Ankara, ss.7-19, 2025 Sürdürülebilir Kalkınma

2. Chapter 19- Medical Genetics

OKTAY Y., AĞIRBAŞLI D., DALVA AYDEMİR S., AKYERLİ BOYLU C., MÜFTÜOĞLU M., YAKICIER M. C.
Current Applications of Biotechnology, Dündar, Munis; Bruschi,Fabrizio; Gartland, Kevan; Magni,Mariapia V.;Gahan, Peter; Deeni,Yusuf, Editör, Erciyes University, Kayseri, ss.299-317, 2015
Metrikler

Yayın

9

Yayın (WoS)

7

Yayın (Scopus)

4

Atıf (WoS)

121

H-İndeks (WoS)

3

Atıf (Scopus)

9

H-İndeks (Scopus)

2

Atıf (Scholar)

245

H-İndeks (Scholar)

5

Proje

3

Açık Erişim

3
BM Sürdürülebilir Kalkınma Amaçları